LGND LOSS ALERT: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors of Important Deadline in Class Action F...

NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Ligand Pharmaceuticals Incorporated securities (NASDAQ: LGND) of the important January 17, 2017 lead plaintiff deadline in the class action filed by the firm.  The lawsuit seeks to recover damages for Ligand investors under the federal securities laws.

To join the Ligand class action, go to http://www.rosenlegal.com/cases-996.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [e-mail] or [e-mail] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Ligand overstated the value of certain Deferred Tax Assets by approximately $27.5 million or 13%; (2) Ligand's outstanding convertible senior unsecured notes due 2019 should have been classified as short-term debt rather than long-term debt as of December 31, 2015; (3) Ligand did not maintain effective controls over the accuracy and presentation of the accounting for income taxes related to complex transactions; (4) in turn, Ligand lacked effective internal control over financial reporting; and (5) as a result, Defendants' statements about Ligand's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-996.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [e-mail] or [e-mail].  Attorney Advertising.  Prior results do not guarantee a similar outcome.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34^th Floor
New York, NY  10016
Tel: [phone]
Toll Free: [phone]
Fax: [phone]
[e-mail]
[e-mail]
[e-mail]
www.rosenlegal.com

Logo - http://photos.prnewswire.com/prnh/20160907/405060LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lgnd-loss-alert-rosen-law-firm-reminds-ligand-pharmaceuticals-incorporated-investors-of-important-deadline-in-class-action-filed-by-firm--lgnd-300367567.html

SOURCE Rosen Law Firm, P.A.

Copyright 2016 PR Newswire